These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9285110)

  • 1. Medical and cost-economy aspects of modern antihypertensive therapy--with special reference to 2 years of clinical experience with losartan.
    Hansson L
    Blood Press Suppl; 1997; 1():52-5. PubMed ID: 9285110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T; Yoshinaga K
    Blood Press Suppl; 1996; 2():78-81. PubMed ID: 8913545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM; Goldberg AI
    Blood Press Suppl; 1996; 2():82-6. PubMed ID: 8913546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor inhibition. A new therapeutic principle.
    Messerli FH; Weber MA; Brunner HR
    Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
    Lacourcière Y
    Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II antagonism: a new avenue of hypertension management.
    Gavras H
    Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
    Lacourcière Y; Lefebvre J; Nakhle G; Faison EP; Snavely DB; Nelson EB
    J Hypertens Suppl; 1994 Jul; 12(2):S49-53. PubMed ID: 7965266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiotensin II receptor antagonists. Clinical relevance].
    Scholze J
    Internist (Berl); 1996 Jun; 37(6):636-42. PubMed ID: 8767999
    [No Abstract]   [Full Text] [Related]  

  • 9. Losartan: a new antihypertensive drug.
    Dubois M; Wilson TW
    Can Nurse; 1997 Jun; 93(6):31-4. PubMed ID: 9233121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M; Bienfait-Beuzon C; Jackson J
    J Hum Hypertens; 2008 Dec; 22(12):845-55. PubMed ID: 18633426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Losartan--a new antihypertensive.
    Drug Ther Bull; 1995 Oct; 33(10):73-4. PubMed ID: 7493558
    [No Abstract]   [Full Text] [Related]  

  • 12. A new antihypertensive class: the angiotensin receptor antagonist.
    Kupecz D
    Nurse Pract; 1996 Mar; 21(3):106, 109, 113-4. PubMed ID: 8710244
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension.
    Goa KL; Wagstaff AJ
    Drugs; 1996 May; 51(5):820-45. PubMed ID: 8861549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G; Burke TA; Carides G
    J Hum Hypertens; 2006 Jan; 20(1):51-8. PubMed ID: 16357874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark].
    Keiding H; Hildebrandt P; Burke T; Carides GW
    Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.